Online, 1 hour
Dr. Manjunath Hegde
Associate Director – Head Of Technology Unit (R&D) – Cambridge Division
FairJourney Bio
Sampling the whole immune response: Design principles for a single B cell antibody discovery workflow
An immunised animal has already solved the hard problems of affinity, specificity and self-tolerance. Antibody discovery from an immune repertoire is therefore a sampling problem, and every stage of a campaign is a chance to miss the clone you were looking for.
This session walks through the design decisions behind a single B cell discovery platform, from a CRO perspective where the balance between quality, speed and cost is critical. It addresses the most valuable information to acquire before each irreversible step in the campaign.
Topics include immunisation design as the first decision, drawing on aggregated data from several hundred legacy campaigns; why the memory B cell and plasma cell compartments hold functionally different repertoires, and how regimen and harvest timing shift the balance; how to match screening technology to scale, target class and required readout, including cell-based assay formats for conformational and multi-pass membrane targets; why sorted events are not hits, and the cost of taking screening output straight into production; and how single B cell output feeds multispecific format scouting and developability selection through mammalian display.
Meet The Expert
Dr. Manjunath Hegde
Associate Director – Head Of Technology Unit (R&D) – Cambridge Division
FairJourney Bio
Dr. Manjunath Hegde is an interdisciplinary scientist and technology leader with over 15 years of experience in drug discovery and more than 10 years specializing in antibody discovery and engineering. He has played a key role in developing innovative platform technologies that advance therapeutic antibody discovery, engineering, and developability assessment.
Currently, Dr. Hegde leads technology innovation programs at FairJourney Bio, driving the development of next-generation antibody discovery and engineering solutions. Before joining FairJourney Bio, he spent more than eight years at GlaxoSmithKline (GSK), where he served as Principal Scientist and Associate Fellow. He holds a PhD in Chemical Engineering from Texas A&M University and completed postdoctoral research at Harvard Medical School’s Center for Engineering in Medicine.
Dr. Hegde has authored over 20 peer-reviewed publications with more than 2,500 citations and has contributed to advances in mammalian display technologies for therapeutic antibody discovery and development.
The Next Generation: Cyto-Mine® Chroma
Automate. Accelerate. Analyze millions of cells in a single day.
Think Cyto-Mine®, but supercharged, enabling multiplexing and greater assay flexibility to fit your needs. It means that you can examine vastly greater numbers of cells — and isolate the most valuable ones— with unparalleled precision.
